Analyst Ratings for [SIBN] SI-BONE, Inc.

8/6/24	Reiterated	Buy	X
SIBN SI-BONE Needham
$27 $19
3/28/24	Initiated	Overweight	X
SIBN SI-BONE Piper Sandler
$25
10/12/22	Initiated	Buy	X
SIBN SI-BONE Jefferies
$20
4/7/22	Resumed	Overweight	X
SIBN SI-BONE Cantor Fitzgerald
$34
6/8/21	Initiated	Buy	X
SIBN SI-BONE Citigroup
$40
3/9/21	Reiterated	Buy	X
SIBN SI-BONE Needham
$35 $34
11/12/18	Initiated	Buy	X
SIBN SI-BONE BofA/Merrill
$23
11/12/18	Initiated	Buy	X
SIBN SI-BONE Canaccord Genuity
$25
11/12/18	Initiated	Mkt Outperform	X
SIBN SI-BONE JMP Securities
$27
11/12/18	Initiated	Overweight	X
SIBN SI-BONE Morgan Stanley
$24

SIBN SI-BONE, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.